The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.
There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...
For patients aged 18 to 64 years with chronic diseases, electronically delivered letter nudges increase influenza vaccination rates compared with usual care.